Cat:GMP-h-PG-II
Awaiting product image
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-h-PG-II Categories , Tag

For more than 100mg, click here for inquiry. >>

Product Details

Genemedi produces core diagnostic ingredients for test of Gastric disease (pernicious anemia) and related syndrome. GeneMedi offers paired diagnostics grade Pepsinogen II (PG II) antibodies (monoclonal antibody, mab) and antigens for Gastric disease (pernicious anemia) rapid test kit of Pepsinogen II (PG II) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Gastric disease (pernicious anemia ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Pepsinogen II(PGII) – The Pepsinogens are gastric acid protease zymogens. They are divided into two distinct immunochemical groups. Pepsinogen I and II. Pepsinogen II is one of 4 aspartic proteinases: PG I, PG II, Cathepsin E and D. Pepsinogen II is produced primarily in the Oxyntic gland mucosa of the stomach, the gastric antrum and the duodenum. It is secreted mainly into the gastric lumen and into circulation. Pepsinogen II has little or no biological activity but in acid is converted to the active enzyme Pepsin which exhibits proteolytic actions. Unlike Pepsinogen I, Pepsinogen II is not normally found in the urine. Patients with pernicious anemia have low to non-detectable levels of Pepsinogen I but normal levels of Pepsinogen II. Pepsinogen II levels are slightly elevated in gastric ulcer. Patients with Zollinger-Ellison’s syndrome exhibit greatly elevated levels.

Product Description

Cat No. of Pruducts

GMP-h-PG-II-Ag01:Recombinant Human PG II Protein

Product Name

Recombinant Human PG II Protein

Target

Pepsinogen II

Alias of Target/Biomarker

#N/A

Expression platform

E.coli

Isotypes

Recombinant Antigen

Bioactivity validation

Pepsinogen II (PG II) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in PG II level test of Gastric disease (pernicious anemia) and related syndrome evaluation

Tag

His

Products description

Recombinant Human PG II Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Genemeidi Omicron Variant Products
test
Previous slide
Next slide

Cat No. of Pruducts

GMP-h-PG-II-Ab01,GMP-h-PG-II-Ab02:Anti-Human PG II mouse monoclonal antibody (mAb)

Product Name

Anti-Human PG II mouse monoclonal antibody (mAb)

Target

Pepsinogen II (PG II)

Alias of Target/Biomarker

#N/A

Expression platform

Hybridoma

Isotypes

Mouse IgG

Bioactivity validation

Human Pepsinogen II (PG II) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Pepsinogen II (PG II) antibodies in PG II level test of Gastric disease (pernicious anemia) and related syndrome evaluation.

Tag

mFc

Products description

Anti-Human PG II mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Pepsinogen II (PG II) antibodies.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1

Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.